- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
NEW YORK CITY, N.Y., USA: Results derived from a study conducted at the University of New York College of Dentistry seem to confirm the assumption that the administration of oral bisphosphonates is connected to dental implant failure. In the case control study more than 300 female patients having experienced failing dental implants were compared to woman whose implants were still in place.
Clinical evaluations at the Department of Periodontology and Implant Dentistry started in early 1997 and were stopped in late 2004. According to the researchers, the clinical data gathered from these examinations showed that in women whose implants failed, the odds of having taken bisphosphonate orally were almost three times higher. Dental implant failure related to the use of oral bisphosphonate also seemed to be more likely to occur in the maxilla.
Neither the quantity or length of bisphosphonate use was evaluated.
Although the new study indicates that the risk for implant failure is very small, the researchers concluded that oral bisphosphonate could pose a risk to successful dental implant therapy and should be handled with caution.
Earlier research on the connection remains largely ambiguous. Latest results from Sweden and Australia have also found small risks of implant failure, whether bisphosphonate was taken by patients before or after implant placement.
To this day, clinical organisation recommends patients who are long-term users to stop taking bisphosphonates during dental implant procedures to avoid complications. The coumpound which is taken orally is usually prescripted to patients suffering from osteoporosis. It can also be applied intravenously as part of secondary bone cancer treatment.
Mon. 29 April 2024
12:30 PM EST (New York)
Root caries: The challenge in today’s cariology
Tue. 30 April 2024
1:00 PM EST (New York)
Neodent Discovery: Neoarch Guided Surgery—from simple to complex cases
Fri. 3 May 2024
1:00 PM EST (New York)
Osseointegration in extrēmus: Complex maxillofacial reconstruction & rehabilitation praeteritum, praesens et futurum
Tue. 7 May 2024
8:00 PM EST (New York)
You got this! Diagnosis and management of common oral lesions
Thu. 9 May 2024
8:00 PM EST (New York)
Empowering your restorative practice: A comprehensive guide to clear aligner integration and success
Mon. 13 May 2024
9:00 AM EST (New York)
CREATING MORE PRACTICE TIME THROUGH EFFICIENCY: IMPROVED ACCURACY AND DELEGATION
Mon. 13 May 2024
1:00 PM EST (New York)
To post a reply please login or register